Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions

SIMPLE SUMMARY: Apoptosis dysergulation is vital to oncogenesis. Efforts to mitigate this cancer hallmark have been ongoing for decades, focused mostly on inhibiting BCL-2, a key anti-apoptosis effector. The approval of venetoclax, a selective BCL-2 inhibitor, for clinical use has been a turning poi...

Descripción completa

Detalles Bibliográficos
Autores principales: Salah, Haneen T., DiNardo, Courtney D., Konopleva, Marina, Khoury, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231978/
https://www.ncbi.nlm.nih.gov/pubmed/34198580
http://dx.doi.org/10.3390/cancers13122974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231978/
https://www.ncbi.nlm.nih.gov/pubmed/34198580
http://dx.doi.org/10.3390/cancers13122974

Ejemplares similares